Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors (ESPERANZA)

NCT06973161 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06973161
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06973161 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors (ESPERANZA)
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
June 10, 2025
Completion date
March 17, 2026
Enrollment
140 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

biliary tract cancer, bladder cancer, cervical cancer, colorectal cancer, endometrial cancer, lung cancer, other tumors, ovarian cancer, pancreatic cancer